Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    9.
    发明授权
    Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia 有权
    邻苯二甲酰亚氨基芳基哌嗪可用于治疗良性前列腺增生

    公开(公告)号:US06780994B2

    公开(公告)日:2004-08-24

    申请号:US10207473

    申请日:2002-07-29

    IPC分类号: C07D29513

    CPC分类号: C07D209/48 C07D401/04

    摘要: This invention relates to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

    摘要翻译: 本发明涉及一系列含有它们的式Iph药物组合物的杂环取代的哌嗪以及用于其制备的中间体。 本发明的化合物选择性地抑制与α-1a肾上腺素能受体的结合,α受体是与良性前列腺增生有关的受体。 因此,这些化合物潜在地用于治疗这种疾病。